Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Johnson & Johnson : Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:58pm CEST

Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Pharmaceutical Research. According to news reporting originating from Beerse, Belgium, by NewsRx correspondents, research stated, "The present study investigated the influence of in vitro dissolution conditions on the in vivo predictability of an amorphous solid dispersion of celecoxib (CCX) in the pH-sensitive polymer Eudragit ® S 100. Different doses of a 25:75 w/w% CCX: Eudragit ® S 100 amorphous solid dispersion (CCX:EUD) were investigated."

Our news editors obtained a quote from the research from Johnson & Johnson, "During in vitro dissolution a significant effect of the pH of the dissolution media on the release of CCX was observed. In fasted state simulated intestinal fluid (FaSSIF) pH 6.5, the release of CCX from the amorphous solid dispersion was comparable to that of crystalline CCX and lower than that of amorphous CCX whereas in FaSSIF pH 7.4, the release was significantly increased compared to both crystalline and amorphous CCX. With a 3-fold increase in the exposure of CCX: EUD compared to crystaline CCX. The in vivo data also suggested that Eudragit ® S 100 was suitable as a carrier in amorphous solid dispersions of CCX. In vitro-in vivo correlation demonstrated that the in vitro data obtained in FaSSIF pH 7.4 was more predictive for the in vivo performance than that obtained in FaSSIF pH 6.5."

According to the news editors, the research concluded: "Consequently, the findings of this study underline that when predicting the in vivo performance of amorphous solid dispersions with pH-sensitive polymers, it is imperative that the in vitro dissolution conditions are carefully considered."

For more information on this research see: Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier. International Journal of Pharmaceutics, 2017;531(1):324-331. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.journals.elsevier.com/international-journal-of-pharmaceutics/)

The news editors report that additional information may be obtained by contacting R. Holm, Johnson & Johnson, Drug Prod Dev, Janssen Res & Dev, BE-2340 Beerse, Belgium. Additional authors for this research include M.M. Knopp, F. Khan, N. Chourak, T. Rades and J. Wendelboe (see also Drugs and Therapies - Pharmaceutical Research).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ijpharm.2017.08.078. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Beerse, Belgium, Europe, Pharmaceutical Research, Drugs and Therapies, Johnson & Johnson.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12:04aJOHNSON & JOHNSON : Pa. court backs $12.8M verdict against Johnson & Johnson sub..
AQ
06/19JOHNSON & JOHNSON : to Host Investor Conference Call on Second-Quarter Results
PR
06/18MARKETS RIGHT NOW : Stocks look to recover from early skid
AQ
06/18JOHNSON & JOHNSON : FDA Approves the Next Generation of Customized LASIK Treatme..
PU
06/18JOHNSON & JOHNSON : Janssen Pharmaceutical - XARELTO Associated with Significant..
AQ
06/16JOHNSON & JOHNSON : Gift Provides Undergraduate Financial Aid and Serves Communi..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated With Significantly Reduced ..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated with Significantly Reduced ..
AQ
06/15KYROS LAW IS INVESTIGATING CLAIMS ON : 1,100 Invokana Lawsuits Alleging Diabetic..
PR
06/14JOHNSON & JOHNSON : Innovation Announces Five-Year Alliance with Boston Universi..
AQ
More news
News from SeekingAlpha
06/1919 'Safer' Dividends From My Readers 36 Most Mentioned June Dividend Stocks 
06/19DIVIDEND SENSEI'S PORTFOLIO UPDATE 3 : 3 Reasons You Should Avoid This Dangerous.. 
06/19The Market Needs A Glum Index - Cramer's Mad Money (6/18/18) 
06/19Readers Wrote-Up 37 Dividend Stocks In May-June Comments 
06/18Jane's May Dividend Income Tracker - Retirement Accounts 
Financials ($)
Sales 2018 81 525 M
EBIT 2018 24 885 M
Net income 2018 16 158 M
Debt 2018 10 673 M
Yield 2018 2,97%
P/E ratio 2018 17,57
P/E ratio 2019 16,22
EV / Sales 2018 4,16x
EV / Sales 2019 3,86x
Capitalization 329 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 144 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880
AMGEN6.39%122 422